India’s tuberculosis death rate has fallen 38% since 2015, outpacing the global decline of 35%, according to the WHO Global Tuberculosis Report 2026 released last Thursday — yet public health network Jan Swasthya Abhiyan India says more than 2.6 lakh Indians still died of the disease in 2025.
The WHO report, published on November 12, also credits India with a 94% treatment success rate among patients with drug-susceptible tuberculosis — meaning TB that responds to standard first-line medicines. The Health and Family Welfare Ministry attributed the gains to intensified screening, AI-enabled chest X-rays, rapid molecular diagnostics and nutritional support under the National TB Elimination Programme, News On AIR reported.
In Plain English: What These Numbers Mean for Patients

- A 38% drop in mortality means the national death rate fell from about 28 per lakh population to about 18.
- A 94% treatment success rate applies only to drug-susceptible TB; drug-resistant TB is tracked separately.
- Nearly 15 lakh of the 48.64 lakh cases found during the latest screening campaign showed no symptoms — which is exactly why screening, not waiting for a cough, matters.
What the campaign actually did, day by day
Between December 7, 2024 and November 8, 2026, the TB Mukt Bharat Abhiyaan brought more than 25 crore people under intensified screening, conducted over 11 crore chest X-rays and ran more than 3 crore nucleic acid amplification tests — molecular tests that detect the bacterium’s genetic material directly.
The Health Ministry, in figures carried by ANI and Medical Buyer, said the drive identified 48.64 lakh new cases, including 14.97 lakh asymptomatic ones, and a second 100-day campaign launched on March 24, 2026 focused on 1.58 lakh high-risk villages and wards.
The technology works as a triage layer: artificial intelligence software flags suspicious shadows on portable chest X-rays so health workers can prioritise those people for molecular confirmation. India funds 96% of its TB programme from domestic resources, according to the ministry’s release.
| Indicator | Figure | Period / comparison |
|---|---|---|
| India TB mortality decline | 38% | 2015–2025; global decline 35% |
| India TB death rate | 28 → 18 per lakh | 2015 → 2025 (ministry estimate) |
| Treatment success, drug-susceptible TB | 94% | 2025 |
| People screened under Abhiyaan | 25+ crore | Dec 7, 2024 – Nov 8, 2026 |
| Chest X-rays / NAAT tests | 11 crore / 3 crore | Same campaign window |
| India’s share of global TB deaths | 23% | 2025 (WHO) |
The 2.63 lakh deaths that temper the celebration
The same WHO report, cited by Jan Swasthya Abhiyan India, records 2.63 lakh TB deaths in India in 2025 and 25.3 lakh notified cases, compared with 26.18 lakh in 2024. Globally, 10.6 million people developed TB and 1.1 million died in 2025, and the disease remains the leading cause of death from a single infectious agent. India accounts for approximately one-fourth of global cases.
The network also flagged a data gap. WHO has kept India’s 2025 incidence estimates under review pending technical calibration of a 50-district sentinel survey, and the annual India TB Report has not appeared on the Central TB Division’s public portal beyond the 2024 edition.

In its letter to the Centre, Jan Swasthya Abhiyan India raised alarm that the Central TB Division’s public annual-report portal still carries no edition of the India TB Report newer than 2024, warning that without an up-to-date, full annual report containing state-wise and district-wise programme performance figures, independent scrutiny and public accountability are hampered, as reported by ETHealthworld on Monday.
Supply chains are the other sore point. Citing an investigation published by The Indian Express in December 2024, the network said intensive-phase fixed-dose combination medicines fell 56.5% in 2023 against 2022, and continuation-phase supplies fell 23%. The Comptroller and Auditor General’s Report No. 8 of 2024 documented anti-TB medicines worth ₹40.75 crore expiring across five Government Medical Store Depots between July 2017 and February 2023.

Spotting seriously ill patients
A study published in BMJ Global Health offers one clinical explanation for falling deaths: Tamil Nadu’s TN-KET programme, India’s first statewide and state-specific differentiated TB care initiative, used five simple checks to spot seriously ill patients at diagnosis and prioritise hospital care.
Against a baseline two-quarter follow-up TB death rate of 6.3%, the state recorded at least a 38% relative reduction across quarterly cohorts from July 2024 to December 2025. The share of patients discharged to continue ambulatory treatment rose from 79% in April–June 2022 to 97% in January–March 2025. The study covered adults aged 15 and over with drug-sensitive TB at public facilities — about 60,000 patients a year.
WHO Director-General Dr Tedros Adhanom Ghebreyesus struck a global note in the report’s release.
India has seen a 38% reduction in tuberculosis (TB) mortality since 2015, compared to a global average of 35%, and a 94% treatment success rate among patients with drug-susceptible TB, according to the World Health Organization’s (WHO) Global Tuberculosis Report 2026. ✍️@BShajan…
“The continued decline in TB cases and deaths is very encouraging, especially given the challenges many countries have faced from funding cuts. Many governments have dug deeper into their own budgets to protect the gains they have made. And yet, more than one million people still die each year from a disease that is preventable and treatable.”
Globally, domestic TB funding rose 14% to US$ 5.6 billion between 2024 and 2025, partly offsetting a decline in international financing of a similar scale. Uptake of the WHO-recommended six-month treatment regimen increased from 18% in 2024 to 42% in 2025.
Yet the worldwide incidence rate of TB has fallen only 14% since 2015 — well behind the 50% reduction milestone set for 2025 — while research funding sat at US$ 1.2 billion in 2023, under a quarter of the US$ 5 billion per year called for by 2027.
Reporting treatment side effects
TB is preventable and curable, but treatment involves multi-drug regimens with real contraindications. Anyone with persistent cough, fever, night sweats, unexplained weight loss or coughing blood should seek testing at a public health facility rather than self-treating — incomplete or improvised treatment is the main driver of drug-resistant TB, which requires longer, more toxic second-line regimens.

Patients on anti-TB therapy should report immediately: yellowing of eyes or skin, visual changes, peripheral numbness or tingling, or worsening breathlessness. People living with HIV, diabetes, malnutrition, or those on immunosuppressive therapy face higher risk of progression from latent to active TB and should discuss preventive therapy with a physician. Pregnant women and children require weight-adjusted dosing under specialist supervision.
What the 2030 scoreboard says
Under WHO’s End TB Strategy, the number of TB deaths must drop by 90% and the rate of new cases by 80% by 2030 relative to 2015. India’s mortality trajectory tracks the first; the second depends on incidence, and that is the number WHO has yet to publish for India.
JSAI has asked for monthly state-wise disclosure of stock levels, stock-out days and emergency procurement, alongside an independent nationwide assessment of medicine availability. The next dated milestone on record: the release of India’s own annual TB report, which the network wants restored to the public portal.
References
- World Health Organization, Global Tuberculosis Report 2026, released November 12, 2026.
- Jan Swasthya Abhiyan India, letter to the Government of India on NTEP implementation, November 2026, as reported by ETHealthworld.
- BMJ Global Health, evaluation of the Tamil Nadu Kasanoi Erappila Thittam (TN-KET) differentiated TB care programme, 2026.
- Comptroller and Auditor General of India, Report No. 8 of 2024.
- Press Information Bureau / Health and Family Welfare Ministry release on WHO Global TB Report 2026 findings, as carried by News On AIR, ANI and Medical Buyer, November 2026.